General Mills Reaffirms Full-Year Guidance as International Profit Jumps 14%. Is the Turnaround Finally Working?

General Mills reported fiscal Q1 2027 revenue of $4.4B, down 3% year over year, while adjusted EPS fell to $0.75 from $0.86 but narrowly exceeded the $0.72 consensus estimate. The revenue decline reflected the U.S. yogurt divestiture; excluding that sale, sales were flat, with U.S. retail, pet and foodservice businesses all declining. Management reaffirmed FY2027 guidance for net sales of -1.5% to +0.5% and adjusted EPS of $3.00-$3.20, below prior-year EPS of $3.55, reinforcing a low-growth outlook despite a 6.8% dividend yield.

Analysis

GIS faces a quality-of-earnings problem rather than an acute earnings miss: portfolio divestitures obscure an underlying U.S. volume challenge, while price/mix is doing the remaining work. That is unfavorable for gross-margin durability because further pricing is likely to face diminishing elasticity, particularly against private label; retailer data and Nielsen/IRI unit trends over the next 4-8 weeks matter more than the modest consensus beat. The international profit acceleration is constructive but too small and potentially FX-sensitive to offset a sustained U.S. reset.

The dividend yield should limit near-term downside only if free-cash-flow conversion remains intact. With earnings guided below the prior year, the key risk is that the market shifts from valuing GIS as a defensive income compounder to valuing it as a slow-growth, high-payout consumer staple, creating multiple compression even without a dividend cut. A weaker read-through would extend to packaged-food peers with similar volume/price tradeoffs—K, CAG and CPB—while retailers with meaningful private-label exposure, including WMT and KR, could gain negotiating leverage.

Consensus may overstate the strategic benefit of divestitures: removing lower-growth assets can improve reported mix, but it also reduces scale absorption and leaves the company more concentrated in mature categories. The upside case requires a demonstrable volume inflection in core brands and sustained margin delivery; absent those, this is a yield vehicle, not a turnaround. Over 6-18 months, health-and-wellness category migration remains a structural headwind unless GIS uses proceeds for accretive, on-trend acquisitions rather than merely defending the payout.

Key Decisions for Investors

• Maintain/establish an underweight in GIS versus XLP over the next 1-3 months; use any post-results relief rally to enter. Thesis is multiple pressure from negative earnings growth and weak U.S. volumes; cover if reported U.S. organic volume turns positive for two consecutive quarters or FY EPS guidance is raised above $3.20.
• Pair trade: long WMT or KR / short GIS, sized market-neutral, for 3-6 months. Private-label share gains and supplier pricing fatigue favor grocers if branded packaged-food volumes remain soft; exit if GIS volume recovers or grocery gross-margin commentary deteriorates materially.
• Do not buy GIS solely for yield until quarterly operating cash flow, capex and dividend cash outlay confirm at least 1.5x free-cash-flow dividend coverage. A coverage miss or debt-funded capital returns would be a catalyst for a sharper downside repricing.
• Watch K, CAG and CPB earnings for corroborating category-unit trends rather than initiating a broad staples short now. A sector-wide volume slowdown would support XLP underweight; isolated GIS weakness would instead favor the single-name short.